stella
beta
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression — Stella
Recruiting
Back to Suicide trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
United States
National Institutes of Health Clinical Center, Bethesda, Maryland
View full record on ClinicalTrials.gov